Tipsheet
What matters at India’s listed companies
Earnings · Pharmaceuticals · Small cap

Venus Remedies Q1 profit more than doubles on 30% revenue jump

Revenue rose to ₹178.80 crore and net profit hit ₹25.53 crore from ₹11.70 crore a year ago. Company remains debt-free.

5 earlier stories on Venus Remedies Ltd.
Mkt cap₹2,603 cr
P/E25.32×
ROE8.08%
Debt / eq.0.00
Div yld0.54%
₹25.53 cr Q1 FY27 net profit, more than doubled YoY

What's new

  • Revenue from operations hit ₹178.80 crore, up 30% from ₹137.13 crore in Q1 FY26.
  • Net profit more than doubled to ₹25.53 crore from ₹11.70 crore.
  • Board approved minor revisions to the Memorandum of Association, a procedural update.

Why this matters

The profit jump is a strong start to FY27, though the previous year's base was weak. The company's zero-debt balance sheet adds flexibility, but sustaining this growth rate is the real test.

What we're watching

  • Whether the revenue run rate can be maintained through the rest of FY27.
  • Any updates on new product launches or market share gains.
  • Shareholder approval for the revised MOA at the upcoming AGM.

The full read

Venus Remedies opened FY27 with a sharp acceleration. Revenue rose 30% to ₹178.80 crore, while net profit more than doubled to ₹25.53 crore from ₹11.70 crore a year ago, driven by higher sales and improved cost efficiency. With zero debt and a clean balance sheet, the company has room to reinvest. The board also approved minor revisions to the Memorandum of Association — a procedural step needing shareholder approval at the AGM. A strong start, but the test is whether momentum sustains.

Questions answered

How much did Venus Remedies' net profit grow in Q1 FY27?
Net profit rose to ₹25.53 crore from ₹11.70 crore in the year-ago quarter, more than doubling.
What drove the profit jump?
Higher sales — revenue up 30% — and improved operating leverage, as costs grew slower than revenue.
Is the company carrying any debt?
No. The company has a debt/equity ratio of 0.00 according to the latest screener data.
What changes were made to the Memorandum of Association?
The board approved revisions to update the object clause to comply with the Companies Act 2013 and reflect current business practices. The changes are procedural and will be placed before shareholders for approval at the AGM.
Mentioned: Q1 FY27 · ₹178.80 cr revenue · ₹25.53 cr net profit
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Venus Remedies Ltd.

Pharmaceuticals
₹2,206 cr
P/E 18.99×

Latest quarter · Jun 2026

Sales₹179 cr
Net profit₹23 cr
Op. margin+19.1%
EPS₹17.18

Strength & growth

Debt / equity0.00×
Current ratio3.31×
Sales CAGR+7.1%
EPS CAGR+46.2%
  1. 20 Jul 2026 · 6:37 PM IST Venus Remedies Q1 profit more than doubles on 30% revenue jump
  2. 8d ago Venus Remedies Q1 net profit more than doubles to ₹25.53 cr
  3. 63d ago Venus Remedies reports audited results and declares dividend
  4. 63d ago Venus Remedies posts 89% profit jump and names new board members
  5. 63d ago Venus Remedies profit jumps 89% as annual revenue hits ₹768.7 cr